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Abstract 
Absorption of Marine vs Non-Marine sources of EPA and DHA 
John S. Ketz 
 
Docosahexaenoic acid (DHA) from algae oil has been incorporated into tissues at a lower level 
and has been less effective than fish oil (FO) at reducing body fat. Our objective was to determine fecal 
excretion of eicosapentaenoic acid (EPA) and DHA from different dietary sources. Male mice (n=100) 
were fed a 12% lipid diet containing soy oil (SO), FO, yeast oil (YO) algae oil (AO), or AO+YO. The AO 
diet was fed to contain amounts of DHA equal to the FO diet, and the YO diet was fed to contain amounts 
of EPA equal to the FO diet. To measure absorption, fecal samples were collected over night once per 
week for 4 weeks, and fatty acid composition was analyzed. Muscle and adipose tissue were collected and 
analyzed for fatty acid composition. There were no differences in feed intake, body weight, or body fat 
(P>0.05). FO-fed mice did have heavier livers (P<0.05). AO+YO-fed mice had greater fecal DHA content 
than AO- and FO-fed mice for the first 3 weeks (P<0.05), and AO-fed mice had greater (P<0.05) fecal 
DHA content than FO-fed mice in weeks 2-4. FO-fed mice had greater fecal EPA than YO- and AO+YO-
fed mice at week one (P<0.05). FO- and YO-fed mice had greater fecal EPA at week 1 than at weeks 2-4 
(P<0.05). FO-fed mice had the greatest muscle tissue EPA content (P<0.05) at weeks 2 and 4. FO-fed 
mice had the greatest adipose tissue EPA and DHA content at week 4 (P<0.05). At week 2, adipose tissue 
of FO-fed mice contained more EPA than adipose tissue of YO-fed mice (P<0.05), and more DHA than 
adipose tissue of AO-fed mice (P<0.05). Thin layer chromatography was performed and verified that the 
oil sources were primarily composed of triglycerides. Positional analysis of the oils was performed with a 
lipase and showed enrichment of DHA in FO at the sn-2 position. In conclusion DHA in FO is more 
available than in AO, because of the position of DHA on the triglyceride structure, and EPA and DHA 
from FO is more highly incorporated than from YO or AO.   
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Introduction 
 
Omega-3 fatty acids have been widely studied for their beneficial effects on cardiovascular 
disease (CVD) and the metabolic syndrome. The leading cause of death in the US is CVD, and the 
metabolic syndrome is becoming a bigger concern throughout the world [1]. The omega-3 fatty acids, 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been reported to lower risk factors 
for the metabolic syndrome [2]. These beneficial effects include lowering serum triglycerides (TG), 
improving cholesterol levels, and decreasing body fat. Different sources of omega-3s can have differing 
effects on the body, even though they contain equal amounts of omega-3 fatty acids [3], including 
differences in incorporation and eicosanoid production. Differences in the position of fatty acids on the 
TG could be a possible explanation for these differences between different sources, which could play a 
role in affecting the lipid digestion, absorption, and transport [4].  
Lipid digestion 
 
 Hydrolysis of TGs starts with lingual and gastric lipase [5]. Lingual and gastric lipases start 
hydrolysis before TGs reach the small intestine, however this hydrolysis accounts for only 10-30% of TG 
digestion [6]. Cholecystokinin, synthesized by I cells in the duodenal mucosa, is released in the duodenal 
and jejunal mucosa in response to the presence of lipid and amino acids in the lumen, and it is the primary 
hormonal drive for release of pancreatic lipase [7]. Cholecystokinin is also responsible for stimulation of 
the gallbladder, along with relaxation of the sphincter of oddi and subsequent release of bile acid into the 
small intestine. Secretin, released in response to lowered pH, acts on a receptor on the pancreas to 
increase cAMP in the pancreas which leads to bicarbonate release. Bicarbonate is important to regulate 
the pH of the small intestine to counter the acidic contents from the stomach [6]. Secretin also enhances 
the effect of cholecystokinin in the release of enzymes from the pancreas [7].    
Pancreatic lipase, the main enzyme involved in TG digestion, acts at the oil-water interface 
instead of penetrating the micelle [8]. Reaction velocity depends on micellar surface area; therefore 
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degree of emulsification is a key component for fat digestion [9]. Bile salts are important for lipid 
digestion, emulsification of the lipids, and helping to create the mixed micelles. People with decreased 
bile acid concentrations have decreased lipid absorption [10]. Lipase alone does not have a bile salt 
requirement for activity, and even is inhibited by bile salts [11, 12]. The bile salt will displace lipase, at 
the oil-water interface, into the aqueous phase. Inhibition also results from a buildup of a detergent layer 
from the bile salts which blocks lipase interaction with the lipids [11]. Lipase inhibition is overcome by 
interactions of colipase with lipase [13]. Colipase is not essential for lipid digestion, but plays a critical 
role, and colipase deficiency will cause a decrease in lipid absorption, especially in high fat diets [14]. 
Lipase and colipase together will create a lipase-colipase-bile salt micelle complex [15, 16], and the 
formation of the complex determines the adsorption of the lipase-colipase complex [17]. Colipase will act 
as an anchor for the lipase; colipase penetrates the lipid layer and anchors the lipase to the lipid layer [18].  
 The structure of human pancreatic lipase was established by using cDNA clones  after isolation 
from the human pancreas cDNA library and mature human pancreatic lipase is a glycoprotein with 449 
amino acids and a molecular weight of 49,558Da [19]. Pancreatic lipase was shown by crystallography to 
contain a globular N-terminal domain, formed by a central β-sheet core, and a C-terminal domain with a 
β-sheet sandwich, and stabilized by 7 disulfide bonds [20]. A surface loop is formed by a disulfide bridge 
between two cysteine residues, and it covers the active site. The loop forms van der Waals bonds with two 
β-loops, the β-5 loop and the β-9 loop [20]. Colipase binds to the C-terminal domain of lipase [21]. In the 
absence of mixed micelles, the lid domain remained closed and the active site shut [22]. When micelles 
are present, there is a conformational change in lipase as the β5 loop hinges back away from the β9 loop. 
This change reveals the active site and creates an electrophilic region with phenylalanine and leucine, 
known as the oxyanion region [23]. Once open, colipase forms two new hydrogen bonds with lipase to 
stabilize the open conformation [23]. Mutations in the Glu15 residue of colipase, which facilitates 
formation or new hydrogen bonds, show a decrease in lipase activity without a decrease in micelle 
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binding, suggesting that colipase is required not only for binding of lipase to the micelle complex but also 
to stabilize the structure [24].   
The catalytic site of pancreatic lipase has been shown, using the crystal structure [25] and site 
mutations [26], to have a catalytic triad of action very similar to proteases, with the serine residue 
following the same motif of proteases. It has 3 conserved amino acids of action in serine, histidine, and 
aspartic acid; however, it has been reported in some lipases that aspartate is not always conserved and can 
be substituted by glutamate [27]. The active site is buried under the long loop lid region of the lipase, and 
this site is exposed once the lid is open [25].The fatty acid binding site is located on top of the central β-
sheet and surrounded by a hydrophobic region [28]. The mechanism of action of lipase has been analyzed 
and is very similar in most species [29, 30]. Aspartic acid forms a hydrogen bond with histidine and 
increases the pKa of the imidazole nitrogen of histidine. This increase turns the histidine into a powerful 
base facilitating the deprotonation of the serine. This deprotonation allows the serine to act as a 
nucleophile, and consequently, it attacks the ester carbonyl group on either the sn-1 or sn-3 fatty acids of 
the TG. This reaction creates a negatively charged tetrahedral intermediate which is stabilized by the 
oxyanion hole. This oxyanion hole is created with threonine, or phenylalanine in human pancreatic lipase 
[20], and leucine. The carbonyl reforms with the glycerol acting as a leaving group. A water molecule 
then donates a proton to histidine and creates a hydroxyl anion. This hydroxyl group then attacks the 
carbonyl carbon of the lipid which makes another negatively charged tetrahedral intermediate, which is 
also stabilized by the oxyanion hole. After the carbonyl is reformed the serine is released, and the 
products diffuse away (Figure 1).  
Fatty Acid and Monoglyceride Uptake into Enterocytes 
 
The pKas of most long chain fatty acids (LCFA) are less than 5, so most of them are ionized at 
physiological pH [31]. A folded conformation of unsaturated fatty acids facilitates their rotation into the 
membrane; although, protonated LCFA’s can easily cross the membrane [32]. A key component of lipid 
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absorption is the unstirred water layer that lines the brush border membrane. Water molecules are trapped 
by a network of mucus and glycocalyx in a layer that is 50-500µm [33]. The key aspect of the unstirred 
water layer is a low pH that is generated by an H
+
/Na
+ 
antiport exchange in the brush border membrane 
[34, 35]. Since LCFAs need micelles to be in an aqueous environment, fatty acids travel through this 
water layer in micelles [36]. Once the LCFAs reach a pH in the microenvironment of the water layer that 
is lower than their pKa they become protonated. This protonation of the LCFAs induces their release from 
micelles near the microvilli [37]. Also, in the protonated form, LCFAs diffuse easier across the membrane 
because of greater membrane permeation [38, 39]. The rounded surface of the microvilli creates a 
favorable environment for the flip-flop of LCFAs in the membrane [32, 40]. Passive diffusion occurs in 
three steps; adsorption of LCFA’s to the membrane surface, a flip-flop action from the external to internal 
portion of the bilayer, and desorption from the internal bilayer into the vesicle [41, 42]. The desorption 
step was shown to be thermodynamically favorable and very fast [42, 43]; albeit, there is controversy 
regarding whether or not the flip-flop step is rate limiting [38, 40].     
Absorption of 2-monoglycerol (2-MG) has not been as extensively studied as absorption of 
LCFAs, and the mechanism is still controversial. Schulthess et al. [44] reported that rate of absorption 
into isolated enterocytes exhibited passive diffusion and agreed with the adsorption and diffusion 
mechanism seen with LCFAs. However Murota et al. [45] and Shiu-Ying et al. [46] reported in Caco-2 
cell lines, that absorption of 2-MG is also facilitated by protein carriers. These two studies found that the 
apical membrane has a higher affinity for 2-MG than for LCFA. The 2-MG can undergo 
interesterification of the fatty acid to sn-1 or 3 positions [47]; the 2-MG pathway is the main pathway in 
fat absorption [48]. 
Triglyceride Repackaging 
 
Below the microvilli is an area called the terminal web that leads into the apical cytoplasm where 
organelles involved in lipid transport, such as the endoplasmic reticulum (ER) and Golgi complex, are 
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located [49, 50]. The ER is made up of smooth (SER) and rough (RER) structures. The RER appears as 
lines of membranes studded with ribosomes, and the SER is interspersed around the RER and 
mitochondria [51]. The Golgi is composed of stacks of parallel sacs consisting of small vesicles on the 
immature face and large vacuoles on the mature face [52]. After a lipid rich meal, lipid will accumulate in 
small vesicles of the SER in the apical cytoplasm and also in the larger Golgi vacuoles that are derived 
from the Golgi saccules [49, 50]. 
The steps to re-esterify free fatty acids and 2-MGs back into TGs require the action of a fatty acyl 
CoA ligase, located in the microsomal fraction, to make fatty acyl CoAs [53]. One such ligase is Fatty 
Acid Transport Protein 4 (FATP4), which exhibits acyl CoA synthetase activity [54] and traps fatty acids 
in the cell with the CoA group, and it is localized in the ER [55]. Fatty acid binding proteins (FABP) 1 
and 2 are expressed in the small intestine [56]. These FABPs are involved with delivering fatty acids to 
the membranes of the organelles involved with fatty acid transport [57]. While FABP1 can bind to two 
LCFAs and other hydrophobic molecules, FABP2 is more restricted to one LCFA [58, 59]. Cistola et al. 
[60] hypothesized that FABP1 transports mainly 2-MG and cholesterol, while FABP2 transports fatty 
acids. The mechanism of delivery between the two proteins is also different; FABP2 has a collision 
mechanism involving ionic interactions, and FABP1 uses a diffusion mechanism [61].  
Fatty acyl CoAs react with 2-MG to form a diacylglycerol (DG), and this reaction is catalyzed by 
monoglyerol acyltransferase (MGAT); MGAT2 and MGAT3 are expressed in the human intestines [62] 
[63]. Once DG is formed, another fatty acyl CoA will react to form TG, catalyzed by diacylglycerol 
acyltransferase (DGAT) [64]; DGAT1 and DGAT2 are expressed in the small intestine. The 2-MG 
pathway for TG re-synthesis occurs in the SER [65], and DGAT1 is the major DGAT enzyme for 
synthesis of TG in the small intestine [66]. This enzyme is localized in the ER membrane and the active 
site faces the ER lumen whereas DGAT2 is located in the cytosolic side [67]. The DGAT1 pathway is 
mostly used for TG synthesis in chylomicron secretion, while DGAT2 is used primarily to increase TG 
storage in the enterocyte and not for chylomicron secretion. The differences in function of DGAT1 and 
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DGAT2 were demonstrated in an experiment by Yamazaki et al. [68]; in the liver, overexpression of 
DGAT1 increased lipoprotein secretion while DGAT2 overexpression led to TG accumulation in the 
cytosol. DGAT1 is non-essential to lipid absorption for knockout mice suggesting compensation from 
DGAT2; however, on a high fat diet, the knock out model accumulated lipid in the enterocytes and 
exhibited a decrease in chylomicrons [69]. Proteins containing carnitine palmitoyltransferase (CPT) 
activity have been isolated from the ER [70]. Evidence suggests that CPT plays a role in transporting fatty 
acyl CoAs into the SER, with inhibitors of CPT decreasing lymph TG after a lipid load [71].  
Chylomicron Formation 
 
Once the TGs are resynthesized in the SER, they need to be packaged into chylomicrons for 
transport (Figure 2). Microsomal triacylglycerol transfer protein (MTP) is expressed in the small intestine, 
specifically the ER, and it is vital to lipid transport [72]. The three functional domains contained inside 
MTP allows it to adsorb with TGs and other neutral lipids, interact with the ER membrane, and bind 
apolipoprotein B48 (ApoB48) [73]. Nascent apolipoprotein, synthesized in the RER, translocates into the 
SER and binds to TGs before translation of ApoB48 is complete [74].  Wu et al. [75] demonstrated that 
MTP and ApoB48 interact with each other. This same group also demonstrated that lipids are key in the 
binding of MTP to ApoB48, where lipid bound MTP associates with ApoB48 up to 5 fold more than 
without lipid. Association with ApoB48 facilitates MTP’s folding into its mature state [76]. In the SER, 
MTP binds and shuttles TGs, for which it has the greatest affinity compared to other lipids [77]. 
Inhibition or a deficiency in MTP decreases TGs in the ER lumen and reduces ability of enterocytes to 
secrete ApoB48 and lipoproteins [78, 79]. If ApoB is not associated with lipid bound MTP, then it 
proceeds through a proteasomal degradation pathway. The ApoB translocates out of the ER, and it is 
ubiquinated and targeted for degradation [80, 81].  
Lipid droplet formation happens in the ER lumen prior to incorporation into lipoproteins. The 
transport of TGs, synthesized by DGAT1, is facilitated by MTP from the membrane into lipid droplets in 
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the lumen [82]. Lipid droplet fusion and its incorporation into lipoprotein particles is promoted by MTP 
[79]. The lipid droplet accumulates TGs in the SER and will fuse with ApoB from the RER [83]. To 
stabilize the lipoprotein, apoAIV is incorporated, and this apoprotein is correlated with lipid absorption 
from the diet [84].  Mansbach and Nevin [85] showed that export from the ER into the Golgi is a rate 
limiting step in TG transport. The lipoprotein buds and forms a pre-chylomicron transfer vesicle (PCTV), 
where FABP1 is involved in SER membrane deformation, leading to this process [86]. The membrane 
protein cluster of differentiation 36 (CD36) has also been implicated in playing a role in the budding of 
the PCTV from the SER [87]. The PCTV contains an exclusive protein, vesicle-associated membrane 
protein-7, that targets the PCTV for the Golgi membrane [88]. Coatomer II proteins (COPII) are required 
for the PCTV to reach and interact with the Golgi, specifically Sec24C and Sec23; these proteins are 
associated with the PCTV until fusion with the Golgi [89]. The COPII protein Sar1b associates with the 
Golgi for which it is required for fusion of the Golgi membrane with the PCTV and its subsequent uptake 
[90]. In the absence of these COPII, the PCTV cannot target and fuse with the Golgi [91].  
Once PCTV fuses with the Golgi, it dumps its contents into the Golgi lumen. Once in the Golgi, 
more processing of the lipoprotein occurs. More apolipoproteins are added to the pre-chylomicron, 
specifically ApoAI [88]; additionally ApoB48 is glycosylated [92]. Vesicles transport the chylomicron in 
the Golgi to the basolateral membrane; these vesicles are released, by reverse exocytosis, into intracellular 
space to the lamina propria [93]. The lacteal, which takes up the chylomicrons into the lymphatic system, 
is located centrally in the core of the lamina propia [94]. Transport and uptake of chylomicrons into the 
lacteal are a topic of much debate. Two conflicting models are 1) paracellular transport by open junctions 
in the lacteal [95, 96] and 2) transcellular transport using closed junctions [97, 98].     
Chylomicron transport through the lymph 
 
Once the chylomicron has been taken up by the lacteal, it is transported throughout the body by 
the lymph system. Hydration affects transport rates of chylomicrons into the lymphatic system, with 
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lymph flow rate and chylomicron appearance in lymph decreased by dehydration [99]. Lymph rate also 
increases when lipid is ingested [100]. The capillaries of the lymphatic system are composed of single 
layer endothelial cells [101]. Mice that had genetic defects in their lymphatic vasculature became obese 
[102]. These same mice showed greater deposition of subcutaneous fat. This observation may be due to 
leaky lymph vessels, where lymph was shown to increase differentiation of adipocytes in vitro [102]. 
Lymphatic vessels merge into collecting vessels called lymphangions that are lined with smooth muscle, 
which allows then to contract [103]. Lymph is transported against the pressure gradient formed and 
eventually dumped into the thoracic duct to enter the circulatory system.  
Lipoprotein Lipase; Structure, Action, and Regulation 
 
Lipoprotein lipase (LPL) is one of the primary enzymes for lipid uptake into tissues. It is 
expressed in many tissues throughout the body, mainly ones that use or store fatty acids such as cardiac, 
skeletal muscle, and adipose tissue [104]. Synthesis of LPL occurs in the parenchymal cells of tissues, 
and its transported as a homodimer to the luminal surface of vascular endothelial cells. LPL is transported 
to the endothelial cells by way of the glycosylphosphatidylinositol-anchored high-density lipoprotein-
binding protein 1 (GPIHBP1) [105]. Defects in GPIHBP1 will cause LPL to stay in the parenchymal cells 
and cause chylomicronemia [106]. Ion interactions with heparin sulphate-proteoglycans and glycosyl 
phosphatidylinositol anchors LPL to endothelial cells [107]. The size of human LPL is about 67,000 Da 
[108]. LPL has two structural domains - an amino-terminal domain that contains its catalytic site, and a 
carboxyl-terminal group that contains its heparin binding site [109]. 
The catalytic site of LPL is very similar to that of pancreatic lipase. It has a serine-aspartate-
histidine catalytic triad, a lid region, and an oxyanion hole stabilized with tryptophan and leucine [109]. 
The cofactor apoC-II, which binds the N-terminal domain, is needed by LPL to become fully active [110]. 
The cofactor for LPL, apoC-II, is found on the surface of lipoproteins. Patients with a defect of the apoC-
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II gene are hypertriglyceridemic [111]. The activity of LPL is greatly decreased in the absence of apoC-II 
[112].  
Regulation of LPL is tissue specific; fasting will increase levels of LPL in muscle tissue while 
decreasing levels in adipose tissue [113]. The site with the highest amount of LPL is in heart muscle 
where its used to provide fatty acids for oxidation. Cardiac LPL has an inverse regulation relative to 
adipose LPL [113]. In adipose tissue, LPL is downregulated when in a fasting state with a decrease in 
activity, and upregulated in a fed state [114, 115].   
An increased expression of LPL is seen by apoAV, which leads to a decrease in TGs; an apoAV 
deficiency causes hypertriglyceridemia [116]. Cyclic AMP-responsive element-binding protein H 
(CREB-H) induces several genes that influence LPL. In a study by Lee et al. [117], mice with a knockout 
of the CREB-H controlling gene, CREB3L3, showed high TG levels, higher levels of the LPL inhibitor 
apoCIII, and higher amounts of TGs in very low density lipoproteins (VLDL) compared to control mice. 
Overexpression of CREB-H in mice was associated with increases in apoCII and apoAIV, activators of 
LPL. Patients with hypertriglyceridemia exhibited defects in the CREB3L3 gene that were non-existent in 
normolipidemic patients [117]. Insulin will increase LPL gene transcription [118]. Glucose also regulates 
LPL activity, post-translationally, with its major regulatory effects being glycosylation of the LPL 
enzyme that is essential for its activity [119]. Peroxisome proliferator-activated receptors (PPAR), 
specifically PPARα and PPARγ, are activators of LPL, where activation PPARα and PPARγ upregulated 
LPL in liver and adipose tissue, respectively [120]. An inhibitor of LPL, apoC-III, is down regulated by 
PPARα [121]. Khan et al [122] demonstrated that supplementing FO in moderate hypertriglyceridemic 
men increased adipose LPL levels and LPL mRNA, which would be a factor in lowering serum TG 
levels.    
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Uptake of Fatty Acids and 2-Monoacylglycerols 
 
 While intestinal LCFA uptake is mostly by diffusion, there is evidence that uptake into other cells 
is protein facilitated [123, 41]. Flip flop rates of LCFA across the plasma membrane are be slow because 
the membrane presents a barrier for uptake [124]. LCFA enter into the cells via CD36, which has been 
identified as a fatty acid translocase (FAT) for LCFA uptake [125]. Mice deficient in CD36 have 
impaired LCFA uptake in heart, muscle, and adipose tissue with elevated fasting levels of plasma TGs 
and LCFA’s [126]. In muscle, CD36 is upregulated by insulin and contractions [127] and it is also 
activated by PPARδ [128]. Forkhead box protein O1 (FOXO1) stimulates recruitment of CD36 to the 
plasma membrane to enhance FA uptake [129]. Also expressed with CD36 are FATP1 and FATP6, which 
have transportation properties across the cell membrane, as well as their acyl-CoA synthetase properties 
[130].   
In order to transfer between intracellular membranes, LCFA must bind to FABP [131]. The main 
FABP in muscle tissue is heart-FABPc that transports fatty acids to the mitochondrial membrane where 
an acyl-CoA synthetase converts it to a fatty acyl-CoA [132]. CPT-I then will convert fatty acyl-CoA to a 
fatty acyl-carnitine for transport into the membrane via carnitine transporters [133]. The fatty acyl-CoA 
will be regenerated once across the membranes and will undergo oxidation for energy in the 
mitochondria. The LCFA can also be resynthesized into TGs and stored in the cells, mostly in adipose 
tissue. The reaction, described by Bell and Coleman [134] and Stam et al. [135], starts with glycerol 3-
phosphate which reacts with the fatty acyl-CoA; this reaction is catalyzed by glycerol-3-phosphate 
acyltransferase. After 2 fatty acyl-CoAs are attached to form phophatidic acid, phosphtidic acid 
phosphatase removes the phosphate group. The last reaction is catalyzed by DGAT; fatty acyl-CoA is 
attached on the existing diacylglycerol to form a TG.  
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Metabolic syndrome 
 
Excessive lipid consumption and storage can lead to obesity and increase risk factors for the 
metabolic syndrome [136]. Metabolic syndrome is a classification for individuals at risk for CVD and 
diabetes. Its prevalence is becoming wide spread worldwide [1]. Metabolic syndrome is defined different 
ways by different organizations, but the main risk factors included are high TGs, increased blood 
pressure, reduced high density lipoprotein (HDL), and a larger than normal waist circumference [137]. 
The leading cause of death in the USA, accounting for over a third of deaths, is CVD [138]. Omega-3 
fatty acids, specifically EPA and DHA, are used as treatment and preventative options for patients at risk 
of CVD. Most people do not consume enough omega-3s in their diets with average consumption of EPA 
and at DHA 0.05 g/day and 0.10 g/day, respectively, while the American Heart Association recommends, 
for patients with CVD 1 g/day each, or 2-4 g/day in patients with high TGs [139].  
Omega-3 Sources 
 
The primary dietary polyunsaturated omega-3 fatty acids (PUFAs) are α-linolenic acid (ALA), 
EPA, and DHA. Because humans do not make the Δ-12 desaturase enzyme necessary to synthesize 
PUFAs, it is important to get adequate amounts of these PUFA’s in the diet. High intake of PUFAs, 
specifically from fish, has been attributed to a decrease in mortality from coronary heart disease [140]. 
Most plant sources do not contain high amounts of EPA or DHA, but rather ALA. The PUFAs 
that are contained in fish, mainly EPA and DHA, are derived from consuming plankton and [141]. ALA 
can be found in high amounts in vegetable products, especially nuts and seeds, including flax, walnuts, 
and chia and also green leafy vegetables [142]. Vegetarian and vegan diets are normally very low in EPA 
and DHA; however, ALA is usually high in these diets [143]. Non-marine sources of DHA and EPA are 
on the market; these sources include algal and yeast oil. Vegetarian, vegan, and meat-eating subjects were 
compared for plasma fatty acids, and subjects consuming vegetarian and vegan diets were had decreased 
EPA and DHA levels [144]. The Δ-6 desaturase enzyme is involved with converting linoleic and linolenic 
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acid to more unsaturated fatty acids, and coupled with elongase, produce arachidonic acid or EPA, 
respectively. These pathways share the same enzyme so there is competition between the two. These 
enzymes are expressed throughout the body, especially in the brain, heart, liver, lung, and somewhat in 
muscle [145]. However the conversion from ALA is low, and usually less than 5% [146]. A meta-analysis 
conducted in humans supplemented with ALA, subjects showed minimal increases in EPA and no 
increases in DHA [147]. In a study comparing DHA incorporation into rat hearts from ALA and DHA 
supplementation, ALA supplemented rat hearts contained 6% more DHA(10%) than controls (4%), but 
10% less than DHA supplemented diets (20%) [148]. ALA supplementation effectively decreases CVD 
risk factors; ALA supplementation with flaxseed decreased serum TGs by 36% and improve the 
LDL:HDL ratio in hyperlipidemic patients [149]. This supplementation lowered LDL in healthy patients 
by 8-18% [150, 151]. However, there has also been work done showing that ALA is not as effective as 
EPA or DHA; in fact supplementation of ALA with overweight patients showed no effects on lipid levels 
[152].  
Algae and Yeast oils 
 
DHA from algae oil, produced primarily from Crypthecodinium cohnii, is used widely as an 
alternative to fish oil, with its most common uses in infant formula, pill supplements, and fortified foods; 
it has been labeled as Generally Recognized As Safe from the Food and Drug Administration [153]. 
Supplementation with AO in hypertriglyceridemic men decreased TGs by 24% with an increase in size of 
LDL particles and decreased particle number [154]. In a study with menopausal women, Stark and Holub 
[155] found a 20% decrease in TG and an 8% increase in HDL, with no change in LDL. In contrast, 
Theobald et al [156] supplemented middle aged men and women with low dose DHA capsules and 
detected increased LDL and total cholesterol, with no decrease in TG levels.  
Although not widely used, yeast oil supplements that are derived from the Yarrowia lipolytica, 
are on the market that are enriched in EPA. There have not been many studies conducted examining the 
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effects of YO. In a rat model, different dosages of EPA from YO, FO and YO showed similar effects in 
decreasing cholesterol [157]. Another study from the same group tested YO in a similar model but with a 
longer testing period and detected decreased total cholesterol in YO-fed rats compared to control, but only 
in a higher dosage [158]. No differences in TGs were observed in any of the groups compared to the 
control in these studies.   
Serum Lipid Regulation 
 
Decreasing levels of LDL reduce atherosclerosis by decreasing the amount of fatty streaks that 
occur in the capillaries [159]. Evidence suggests that EPA and DHA can increase HDL [160]; however, 
this effect is debatable. Patients with hypercholesterolemia, supplemented with EPA over 4-6 years, saw a 
decrease in LDL levels by 25%, and a resulting 19% decrease in major coronary events compared to 
control patients [161]. Mice fed FO exhibited a down regulation of LDL receptor gene expression in 
hepatic tissues [162]. Patients with type-2 diabetes given EPA and DHA showed an increase in HDL and 
reduced VLDL [163]. However, there have been mixed results on the effects of EPA and DHA on LDL 
levels; some studies found no change when compared to controls, as demonstrated by Skulas-Ray et al 
[164] where supplementation of FO in healthy moderately hypertriglyceridemic patients showed no 
change in LDL levels.   
The effect of FO and concentrated EPA/DHA supplementation on serum TG levels has been 
extensively studied. Fish oil supplementation is used pharmacologically in patients with severe 
hypertriglyceridemia to help lower TG levels [164]. In an observational study that evaluated overweight 
patients with type 2 diabetes, fish consumption was negatively correlated with serum lipid levels and 
showed an inverse relationship with TG levels [165]. In patients with type-2 diabetes, EPA and DHA 
supplementation reduced TGs [163]. In a study with moderate hypertriglyceridemic patients, low doses of 
FO supplementation did not reduce TG levels; however, with high doses of 3.4 g/day of EPA+DHA, TGs 
were lowered by 27% [164]. 
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One of the primary TG synthesis regulators is transcription factor sterol regulatory element-
binding protein 1c (SREBP1c), that stimulates synthesis of lipogenic genes involved in TG synthesis. 
Once synthesized, TGs are packaged into VLDL and secreted into circulation [166]. In the ER membrane, 
SREBP1c is synthesized as a precursor protein. Sterol deficiency stimulates sterol-regulatory element 
binding protein cleavage-activating protein to move SREBP1c to the Golgi where proteolytic cleavage of 
SREBP1c allows the mature protein to translocate to the nucleus, bind to sterol response elements, and 
induce gene transcription [167]. PUFAs decrease SREBP1c transcription, which is regulated by Liver X 
Receptor (LXR) [168]. To stimulate SREBP1c transcription, LXR will heterodimerize with Retinoid X 
Receptor (RXR) and will bind to a response region in the promoter of the SREBP1c gene. PUFAs can 
bind to LXR, which will inhibit LXR binding to this region, thus suppressing stimulation of SREPB1c by 
LXR [169]. In mice fed a high fish oil, diet SREBP-1c protein levels were decreased by 57% in response 
to decreased SREBP1c mRNA (-86%) levels in the liver compared to controls [170]. DHA prevented 
LXR activation of SREBP1c transcription [171]. Also DHA regulates SREBP1c by proteosomal 
degradation of nuclear SREBP1c [172]. 
Numerous other genes are regulated by LXR, including Cyp7x, LPL, SCD1, and sterol 
transporters including the ATP-Binding Cassette gene family ABCA1 and ABCG5/G8 [173]. Oxysterols 
are the primary agonist for LXR, and binding of LXR to them will increase gene transcription for LXR 
targeted genes [169]. PUFAs interact with the receptor on LXR for oxysterols and act as an agonist. Cells 
treated with LXR agonist in PUFA media had a reversal of the inhibitory effects of PUFAs [174]. 
However Pawar et. al. [168] demonstrated, in a rat model, that genes involved with LXR regulation and 
that did not require SREPB1c interaction were unaffected after FO feeding. 
 PPARs are nuclear receptors that function as ligand-activated (such as PUFAs) transcriptional 
regulators of genes which control lipid and glucose metabolism [175]. A main regulator of lipid 
homeostasis, PPARα, regulates genes including CPTI and CPTII, LPL, and uncoupling protein I (UCPI) 
[176]. Also regulated by PPARs are LXRs, which will diminish their lipogenic effects [177]. Omega-3 
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PUFAs affect PPARα, δ, and γ; however, their metabolites, specifically eicosanoids, are much more 
potent activators, especially for PPARα [178].   
Body fat regulation 
 
Rats fed a high fat diet (48% of calories), with 15% consisting of FO, exhibited decreased 
subcutaneous and visceral adipose tissue weights when compared with a high fat control [179]. Rats fed a 
20% FO diet had a reduction in size of adipocytes with no reduction in number compared to 20% lard 
control [180]. Ruzickova et al. [181] observed decreased epididymal fat in mice fed high fat diets (35% 
by weight) containing EPA and DHA with limited effect on subcutaneous fat compared to control. In 
their study, the anti-adiposity effect was promoted by a lower EPA/DHA ratio. Mice that were fed a high 
FO diet (32% weight) after reaching an obese state on control (32% fat by weight) lost 24% bodyweight 
after 6 weeks [182]. Reduction in adipose weights for rats fed FO diets was attributed to a reduction in 
adipocyte hypertrophy, and a dose dependent reduction of lipid mass from FO [183]. 
 Carnitine palmitoyltransferase I is an enzyme used to shuttle fatty acids into mitochondria for 
oxidation. CPT-I is increased in rat skeletal and cardiac muscle when animals intake FO compared to an 
olive oil control [184]. AMP-activated protein kinase (AMPK) is a regulator of CPT-I, it is activated by 
EPA in adipose and skeletal muscle [185, 186]. Supplementation of PUFAs increase uncoupling protein-3 
(UCP) in skeletal muscle; UCP3 is less efficient than mitochondrial oxidation for usage of substrates for 
ATP [187, 188]. In a study by Flachs et al. [189], mice were fed a high fat diet of flaxseed high in ALA or 
flaxseed mixed with EPA and DHA. Mice fed the EPA/DHA diet had less epididymal fat than the 
flaxseed-fed mice. They also exhibited increases in CPT-I and nuclear respiratory factor-1, a promoter for 
mitochondrial synthesis [190], in the epididymal fat but not in the subcutaneous fat.   
 
 
 
 
 
17 
 
Effects of Source 
 
Although ALA is an essential fatty acid and can be converted to EPA and DHA, supplementary 
and dietary EPA and DHA are more effective than ALA in terms of cardio protective effects. Body fat 
and cholesterol decreases are not observed with ALA; however, it has shown some similar effects in 
lowering serum TG levels [191]; whereas other studies have shown ALA supplementation ineffective at 
lowering TG levels [192]. EPA and DHA are equally effective in increasing the clearance rate of dietary 
TGs [193]. EPA and DHA also have similar effects in lowering serum TGs [193]. One difference between 
PUFAs is that DHA can increase HDL cholesterol concentrations, while EPA and ALA do not [194]. 
While both EPA and DHA lower serum TG levels, some studies have shown that DHA can be more 
effective [195]. Differences in effects on nuclear receptors have been noticed in some studies. EPA is a 
more potent activator of PPARα [196] and PPARδ [197]. EPA and DHA reduce SREBP1c mRNA, but 
DHA is more effective with longer lasting effects [172]. However DHA reduces the nuclear presence of 
SREBP1c protein while EPA did not [172]. 
Different sources of omega-3 fatty acids could influence absorption of omega-3s from the diet. 
When fed equal amounts of DHA in the diets, AO was less effective in lowering serum TG than FO 
[198]. AO-fed mice required twice the amount of dietary DHA to elicit the same amount of DHA 
incorporation into tissues as FO-fed mice [199]. These differences could possibly be due to differences in 
the oils; specifically the positional differences on the TGs. Yoshida et al. [3] showed that seal oil 
containing diets, which has asimilar fatty acid content as FO, had less EPA and DHA recovered in lymph 
compared to FO containing diets when fed to rats. The main difference between FO and seal oil is that 
EPA and DHA are mostly localized at the sn-1/3 position in seal oil while they are primarily at the sn-2 
position for FO.  
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Introduction: 
 
  With the widespread prevalence of metabolic syndrome and cardiovascular disease (CVD), the 
leading cause of death in the United States [138], there has been much interest to find preventative 
measures. Metabolic syndrome is usually classified as patients with high serum triglycerides (TGs), 
increased blood pressure, and reduced high density lipoprotein (HDL) [137]. Polyunsaturated fatty acids 
(PUFAs), specifically the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), are being used as treatment and preventative measures for patients at risk of CVD and with high 
TGs [2]. The primary source for these omega-3s is fatty fish and fish oil (FO). FO supplementation 
decreases low density lipoprotein (LDL) levels while decreasing CVD risk [161]. FO also decreases 
serum TG levels in patients [163, 164].  
 Alternative sources to FO have been investigated for sustainability and vegetarian reasons. Algae 
oil (AO) from Crypthecodinium cohnii is now a common source of DHA, and it is used for DHA 
supplementation in infant formula [153]. AO supplementation decreases serum TG [154, 155] while also 
lowering LDL levels compared to an olive oil control [154]. Although not very common, yeast oil (YO) 
from Yarrowia lipolytica is an alternative for EPA supplemention. Few investigations on the effect of YO 
have been conducted, although it has been shown to decrease cholesterol levels in a rat model [158].  
 Previous studies from our lab showed marked differences in tissue fatty acid composition of DHA 
and in serum lipid levels between FO and AO-fed mice. When mice were fed equal amounts of dietary 
DHA, FO-fed mice had a greater decrease in serum triglycerides and total cholesterol than the AO-fed 
mice [198]. AO-fed mice required 3.5-5 times as much dietary DHA to cause a similar reduction in serum 
cholesterol [199]. AO-fed mice fed twice the dietary DHA as FO-fed mice had the same percentage of 
DHA incorporation into tissues [199].  
 This study explored the reasons why AO-fed mice had less DHA incorporation into tissues than 
FO-fed mice. We also used YO to compare the effect of EPA vs DHA. We therefore tested the hypothesis 
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that absorption of omega-3 fatty acids in different by measuring percent of lipid in fecal samples of mice 
fed FO, YO, and AO. Lipid classes of the oils were measured as well as positional distribution of the 
omega-3 fatty acids on the triglycerides in the oils.  
Methods 
 
Research design 
All animal procedures were conducted in accordance with an approved Institutional Animal Care 
and Use Committee protocol. All diets were based on the AIN-93G diet with soy isolate as the protein 
source and 12% lipid (Table 1). Menhaden Fish oil (FO) (Dyets Inc., Bethlehem, PA), Algal vegetable oil 
from Crypthecodinium cohnii (AO) (Martek Biosciences Corp., Columbia, MD), and Yeast oil from 
Yarrowia lipolytica (YO) (Futurebiotics Corp., Hauppauge, NY) replaced soy oil (SO) (Dyets Inc.). On a 
weight/weight basis, these diets provided 7.03g/kg DHA and/or 12.64g/kg EPA, which was the level of 
DHA and EPA provided by the 12% fish oil diet (Table 2). Male ICR mice (n=100) were obtained from 
Harlan Inc. (Indianapolis IN.) and housed individually. They were acclimated to the control soy oil 
powdered diet for 1 week. Mice were blocked by body weight and randomly assigned to one of 5 
treatments. Treatments were SO, FO, AO, YO, or AO + YO. There were 20 mice assigned to each diet. 
Mice were fed for either a 2 week period or a 4 week period.  
Seven mice from each diet assigned to receive the experimental diets for 4 weeks were randomly 
selected and placed in metabolism cages to collect fecal samples. Once a week for four weeks, mice were 
placed in metabolism cages overnight and fecal samples were collected and stored at -20°C. After 2 
weeks, half of the mice from each diet were euthanized, following 5 hours of fasting, and then weighed to 
determine a final body weight. Mice were killed by CO2 asphyxia and bled via cardiac puncture. Liver, 
heart, brain, retroperitoneal and epididymal fat pads, and thigh muscle samples were collected and 
weighed. Samples were put into 2mL cryogenic vials (Fisher Scientific, Pittsburgh, PA), flash frozen in 
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liquid nitrogen, and stored at -80°C. Body fat index was calculated as ((retroperitoneal fat pad + 
epididymal fat pad)/total body weight)x100.  
Muscle and adipose tissue fatty acid extraction  
Muscle (0.25-0.5g) and adipose (0.05-0.1g) tissues were extracted using the method of Park and 
Goins [200]. Samples were put into a 10mL glass tube, and 200µL methylene chloride and 0.5M NaOH 
in Methanol were added. A 1ml aliquot of C17:0 standard (0.2mg/mL) was added, and the tube was 
flushed with nitrogen gas. Samples were then put into a water bath at 90°C for 30min and subsequently 
cooled to room temperature. Two ml of 14% boron triflouride, in methanol, was added to the tubes; these 
tubes were flushed with nitrogen gas, vortexed, and put into a water bath at 90°C for 30min. Samples 
were then cooled to room temperature, and 2mL hexane and 2mL water were added. Samples were 
vortexed and allowed to sit until the phases separated. The hexane layer was transferred, using a glass 
pastuer pipet to a clean 10mL tube to which 1g of sodium sulfate was added. The hexane layer was 
subsequently transferred to a 1.8mL clear, screw top GC vial (Chromatograph Research Supplies Inc., 
Louisville, KY) and stored at 4°C. A Suplecowax 10 column (60 m × 0.53 mm × 0.5-μm film thickness; 
Supleco, Bellefonte, PA, USA) was used. Column temperature was 160°C for 10 minutes, and then it was 
increased 5°C per minute to 220°C and held for up to 60 minutes. Injector temperature was 250°C, and 
detector temperature was 260°C. Fatty acids were identified by retention times compared to mixed fatty 
acid methyl ester standards (GLC-96, GLC-502, and GLC-455; Nu Chek Prep, Elysian, MN). 
Fatty acid extraction and methylation of fecal samples  
Fatty acids were extracted by a modified version of the method described by Bligh and Dyer 
[201]. Fecal samples (0.05-0.3g) were ground using a mortar and pestle, weighed, and placed in 35-mL 
Teflon lined screw cap glass centrifuge tubes. One mL of a C19:1 standard (0.2mg/mL) was added to the 
samples. Five ml of a Trizma/EDTA solution (50mM Tris HCL, 1mM EDTA-disodium salt) was added 
and samples were vortexed for 60sec. Twenty mL of 2:1:0.015 chloroform: methanol: glacial acetic acid 
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(vol/vol/vol) were added, and  samples were vortexed. Tubes were then centrifuged at 900g at 10°C for 
10min. The lower layer was transferred by glass Pasteur pipet, and filtered through 1-PS filter paper into a 
new 35-mL Teflon lined screw cap glass tube. Ten mL of 4:1 chloroform : methanol (vol/vol) was added; 
the mixture was vortexed for 15sec, centrifuged as before, and then the lower layer transferred over the 
filter paper again. The 2:1 chloroform:methanol mixture was used to rinse the filter paper and funnel. 
Tubes were then dried under nitrogen gas on a 60°C heating block. To methylate the samples, the method 
of Fritshe and Johnston [202] was used; four mL of a 4% sulfuric acid solution, in anhydrous methanol, 
was added to samples in the 35-mL glass tubes.  Samples were then incubated in a water bath at 90°C for 
60min, cooled to room temperature, and 3mL of deionized distilled water added to stop the reaction. 
Eight mL chloroform was added and samples were vortexed for 30sec, then centrifuged as previously 
described. Each sample was filtered through sodium sulfate, rinsed with chloroform, and collected in a 
10mL screw cap glass tube. Samples were then dried under nitrogen on a 60°C heating block and re-
suspended in 3mL of hexane. The hexane solution, containing the sample, was then transferred to a 9mm 
gas chromatography screw vial (Agilent Inc., Santa Clara, C.A.) and stored at -20°C to be analyzed by 
gas chromatography. Fatty acid methyl esters were analyzed using a Varian CP-3800 gas chromatograph 
(Agilent Inc.) with a flame ionization detector. A WCOT fused silica capillary column (100-m length, 
0.25-mm inside diameter; Agilent Inc.) was used to separate fatty acid methyl esters. CP-Sil 88 was used 
as the stationary phase. Nitrogen was used as the carrier gas, and a 10:1 split ratio was employed. Oven 
temperature was held at 140°C for 6min, then increased to 220°C, at a rate of 4°C/min, and held for 
37min. The total separating time was 63min. The injector temperature was held at 270°C, and the detector 
temperature was 300°C. Sample fatty acid methyl ester retention times were compared to a standard 
(Supelco™ quantitative standard FAME 37; Sigma-Aldrich, St. Louis, Mo.) fatty acid methyl ester 
retention times for identification.  Peak area was computed by an integrator using the Star GC workstation 
version 6 software (Agilent Inc.).  Fatty acid composition was reported as a percentage of total fatty acids 
identified. 
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Thin Layer Chromatography  
Lipid classes of the oils were analyzed using thin layer chromatography. A 10µL sample of oil 
was  dissolved in 1:1 chloroform:methanol (vol/vol) and spotted onto Whatman K6F silica plates with 
60Å pore sizes (Cobert Associates, St. Louis, MO). A 10µL sample of a TLC standard (TLC 18-5, Nu 
Chek Prep) was spotted along with the samples as well as a triglyceride and free fatty acid standard 
(Triolein and Oleic acid, Nu Chek Prep) to compare bands. Plates were put into a mobile phase solvent 
consisting of a 80:20:1.5 mixture of hexane: diethyl ether :acetic acid solution (vol/vol/vol). The plates 
ran for 70min until the mobile phase reached the end of the plate. Plates were then air dried for 5min, they 
were charred for imaging by covering in a 50% sulfuric acid in-water solution and heated for 45min. 
Images were taken using a Fluorchem 8000 densitometer with transluminating white light (Alpha 
Innotech Corp, San leandro, CA).  
Triglyceride fatty acid position 
We followed the procedure of Smith et al. [203], where 40µL of each oil was added to 1 mL of 
buffer containing 1 mg/mL Triton X-100, 0.04 M Tris, and Borate of 0.05M (pH 7.2); reactions were 
carried out in a 12mmx75mm polypropylene disposable tube (Fisher Scientific, Pittsburgh, PA, U.S.A.). 
Samples were sonicated for 3min for complete emulsification. Samples were then transferred to a 35mL 
Teflon lined screw cap glass centrifuge tube, to which 200 units of porcine pancreas lipase (Sigma-
Aldrich, St. Louis, Mo., U.S.A) was added. This lipase was used in lieu of R. arrhizus lipase as described 
by Smtih et al. A second set of samples were run without the lipase. Samples were then digested for 
60min at in a 37°C water bath. The reaction was terminated by addition of 0.5mL 1 N acetic acid and 3 
mL chloroform/methanol (2:1 vol/vol). The samples were then separated by TLC plate as previously 
described without charring to isolate the monoglycerides from the digested samples. The samples were 
assayed with a monoglyceride standard (Monoolein, Nu Chek Prep, Elysian, MN, USA) to confirm the 
location on the plate. The monoglyceride fraction from the digested samples and the triglyceride fraction 
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from the undigested samples were scraped into a new 35mL glass tube. Samples were then methylated 
according to the Smith procedure [203] by incubating in 1mL, 0.1 N NaOH in methanol for 30min at 
65°C. Lipids were extracted using 3x3 mL hexane, evaporated under nitrogen gas on a 60°C heating 
block, and resuspended in hexane to have 5mg lipid/mL hexane. Samples were stored in 9mm, gas 
chromatography screw vials, and fatty acids were analyzed as previously described.  
Statistics  
Data were analyzed by ANOVA testing the main effects of diet and block using the proc mixed 
procedure, with Pearson correlations analyzed using the proc corr procedure, of SAS version 9.3 (SAS 
institute Inc., Cary, NC, U.S.A.). No diet x block interactions were detected so this was removed from the 
model. Treatment differences were determined by difference of least square means. All data is reported as 
means ± Standard Error for all data. P<0.05 was considered significant and trends were noted at P<0.10.    
Results:  
 
Body composition analysis:  
No differences in average daily feed intake or final body weight (Table 3) were detected. There 
was a trend (P<0.10) in body fat index for FO- and YO-fed mice to be leaner than AO+YO-fed mice 
(Table 3). Relative brain weights of YO-fed mice were greater than those of FO-, AO-, and AO+YO- fed 
mice (P<0.05) at week 2; however, there was no difference at week 4. Relative liver weights (Table 3) of 
the FO-fed mice were greater than those of the AO- and SO- fed mice (P<0.05) at week 2. Relative liver 
weights of the YO-fed mice were greater than those of the SO-fed mice (P<0.05) at week 2. At week 4, 
relative liver weights of the FO-fed mice were greater than those of all the other diets (P<0.05). diet did 
not affect relative heart weight (Data not shown).  
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Fatty acid composition of tissues 
 Muscle EPA percent fatty acids (Figure 3a) was greater at week 2 from FO-fed mice than from 
mice on other diets (P<0.05), while the AO+YO- and YO-fed mice muscle EPA were greater than AO- 
and SO-fed mice muscle EPA(P<0.05). At week 4 FO-fed mice had the greatest EPA percent in muscle 
(P<0.05), and AO+YO-fed mice muscle contained more EPA than the AO- and SO-fed mice (P<0.05); 
muscle EPA of YO-fed mice was greater than that of SO-fed mice (P<0.05). Muscle DHA percent 
(Figure 3b), at week 2, was greater in FO-fed mice than muscle of YO- and SO-fed mice (P<0.05), and 
muscle of AO-fed mice contained more DHA than muscle of SO-fed mice (P<0.05). At week 4, FO-, AO-
, and AO+YO-fed mice muscle DHA was greater than that of muscle from YO- and SO-fed mice 
(P<0.05). 
Adipose EPA percent (Figure 4a) at week 2 was greater in adipose tissue of FO-fed mice than in 
adipose tissue of SO-, YO-, and AO-fed mice. Adipose EPA was greater in YO- and AO+YO-fed mice 
than in SO- and AO-fed mice (P<0.05) at week 2. At week 4, FO-fed mice had the greatest percent of 
adipose EPA; YO- and AO+YO-fed mice had a greater EPA percent than SO- and AO-fed mice (P<0.05). 
Adipose DHA percent (Figure 4b) at week 2 was significantly greater in FO-fed mice compared to SO-, 
AO-, and YO-fed mice ; AO+YO-fed mice had a greater muscle DHA percent than SO- and YO-fed mice 
(P<0.05). At week 4, FO-fed mice adipose contained more DHA than all other treatments, while AO+YO 
fed mice adipose had a greater percent than SO-fed mice (P<0.05).     
Fatty acid composition of fecal samples 
Diet or week did not affect (P>0.05) percent of total lipid excreted (data not shown). Percent of 
EPA in fecal lipid (Figure 5a) was highest in FO-fed mice at week 1 (P<0.05), and feces of AO+YO- and 
YO-fed mice contained more EPA (P<0.05) than SO- and AO-fed mice. AO-fed mice feces contained 
more EPA than SO-fed mice (P<0.05). At weeks 2-4, AO+YO-, YO-, and FO-fed mice generated greater 
fecal EPA than SO- and AO-fed mice (P<0.05). FO- and YO-fed mice feces contained more EPA at week 
 
 
26 
 
1 than at weeks 2-4 (P<0.05); AO+YO-fed mice generated greater amounts from week 1 than week 2 
(P<0.05). The AO-fed mice generated more fecal EPA at week 1 than at weeks 2 and 4 (P<0.05).     
Fecal DHA (Figure 5b) was greatest for AO+YO-fed mice at weeks 1-3 (P<0.05). FO- and AO-
fed mice produced more fecal DHA at week 1 than did SO- and YO-fed mice (P<0.05). Fecal DHA was 
similar for FO- and AO-fed mice. At weeks 2 and 3, AO-fed mice had greater fecal DHA content than 
FO-fed mice (P<0.05). At week 4 AO- and AO+YO-fed mice generated the most fecal DHA (P<0.05); 
FO-fed mice fecal DHA was greater than that of the SO and YO-fed mice (P<0.05). Percent DHA in fecal 
lipid for AO+YO-fed mice was greater at weeks 1-3 than at week 4 (P<0.05).  
Thin Layer Chromatography 
 Oils were separated by TLC with triglyceride, phospholipid, free fatty acid, cholesteryl ester, and 
cholesterol standards. All of the oils had visible bands in line with the triglyceride standard and no other 
bands were visible (Figure 6).  
Positional analysis 
An equal distribution of fatty acids in a TG would give 66% at the sn-1/3 positions and 33% at 
the sn-2 position. FO exhibited an unequal fatty acid distribution of DHA with 62% at the sn-2 position 
and 46% EPA at the sn-2 position (Table 4). YO and AO had relatively equal distribution of EPA (32%) 
and DHA (40%) respectively.   
Discussion: 
 
 Previous studies from our lab showed, when comparing AO and FO, that FO caused a decrease in 
body fat and greater DHA incorporation compared to AO, with no changes in BW or feed intake [198]. 
AO is required to be fed at double the amount of dietary DHA in order to get incorporation similar to FO-
fed mice [199]. We conducted this experiment to better understand the effects of EPA in FO and to 
explain differences in tissue incorporation between AO and FO in mouse diets.   
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Similar to those previous results [198] we detected effects of diet on final body weight or average 
daily feed intake. The trend for a lower body fat index in FO- and YO-fed mice versus AO+YO-fed mice 
was unexpected; in fact, we expected to see differences between control and experimental diets and we 
did not. We have no explanation as to why this difference occurred. Although there was no difference in 
brain weight, relative brain weight when compared to body weight was greater for YO-fed mice at week 
2. We attribute the difference in relative brain weight to numerical differences with body weight and brain 
weight. DHA is normally associated with brain development [204], so any differences we did see we 
thought would have been with the AO or FO diets. FO-fed mice had greater relative liver weights which 
often relates to liver lipid; nonetheless, no differences in total lipid percent or TG content were observed 
[205].  
We measured fatty acid composition of adipose and muscle tissue to identify where EPA and 
DHA are incorporated. We observed very little EPA and DHA in adipose and muscle tissue for SO-fed 
mice. With incorporation of EPA and DHA into adipose and muscle tissue, it was expected that SO-fed 
mice would have the lowest amount because there was minimal in the diet and conversion from ALA to 
EPA is poor. Moreover subsequent conversion of EPA to DHA is not substantial [194] and there was not 
a lot of ALA in the diet, about 8% of lipid. There was more EPA and DHA in muscle than adipose tissue 
in SO-fed mice since there was little in the diet to be stored in the adipose tissue while conversion from 
ALA would be needed for incorporation into muscle. EPA on the other hand shows some conversion to 
DHA, as well as DHA retro conversion back to EPA [194]. These interconversions explain why we see 
moderate amounts of DHA in the tissues from the YO-fed mice and moderate EPA from the AO-fed 
mice. We detected the greatest amount of EPA and DHA in adipose and muscle tissues for the FO 
treatment. Treatment could be due to differences in digestibility.  
Because treatment affected tissue DHA and we measured fatty acid composition of fecal samples 
as a potential reason for these differences. We detected greater amounts of DHA in fecal lipid for AO 
treatments compared to the FO treatments; AO+YO-fed mice yielded the greatest fecal DHA from weeks 
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1-3.  Greater excretion of DHA from the feces of AO-fed mice could explain why there is less 
incorporation of DHA into their tissues (i.e. less was absorbed).  We thus performed a correlation 
analysis, and observed a positive correlation between fecal DHA (average of 4 weeks) and both adipose 
tissue DHA (r = 0.46, P = 0.0048 ) and muscle DHA (r = 0.48, P = 0.0034 ) indicating that mice that were 
fed DHA (FO, AO, and AO+YO) had greater fecal and tissue DHA.  However, when the correlation 
analysis was performed only with mice receiving DHA in the diet no significant correlations were 
observed (fecal-adipose r = 0.011, P = 0.96; fecal-muscle r = 0.41, P = 0.065).  The AO+YO-fed mice, 
which had greater fecal DHA and equal tissue DHA as the AO-fed mice may be affecting this analysis.  
Alternatively, the smaller sample size (n = 21) of mice fed DHA and used for the fecal analysis could be 
impacting our ability to detect a significant correlation. We did not detect treatment differences in EPA 
between FO and YO groups; however, time affected fecal losses, and the greatest losses in EPA occurred 
at week 1. This observation might be due to adaptation to the different oils by the mice to increase 
absorption of EPA. Similar to DHA, fecal EPA (average of the 4 weeks) was positively correlated with 
both adipose (r = 0.71, P = 0.0001) and muscle (r = 0.54, P = 0.0009) EPA when all mice (n = 35) were 
included.  When only mice fed EPA (FO, YO, and AO+YO) were included no significant correlations 
were detected (fecal-adipose r = 0.23, P = 0.31; fecal-muscle r = 0.17, P = 0.47).   
Since different lipid classes have different absorption mechanisms [206]; we tested the 
composition of the oils using TLC to determine if there are composition differences that could explain the 
differences in fecal excretion. These data revealed that all treatment oils were primarily composed of 
TGs, consistent with the manufacturers’ labels. 
Since there were no differences in lipid classes for the oils, we tested the positional distribution of 
fatty acids on the TGs. FO had an unequal distribution of EPA and DHA, with 62% of its DHA and 46% 
of its EPA at the sn-2 position. We detected 32% of EPA at the sn-2 in the YO and 40% DHA at sn-2 in 
the AO. This finding is close to equal distribution, where you would expect 33% sn-2 and 66% sn-1/3. 
Wang et al. [207] did a similar digestion of menhaden oil using porcine pancreas lipase, and they saw an 
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enrichment of DHA at the sn-2 position. They also showed enrichment of EPA for menhaden oil, a larger 
difference then we determined. Enrichment of DHA at the sn-2 position of FO could explain differences 
in absorption as suggested by fecal DHA losses. We do not see diet differences in EPA absorption, which 
corresponds to the lipase digestion showing EPA was more equally distributed on the triglycerides of the 
oils than DHA. In a study by Christensen et al. [4] EPA and DHA were more readily absorbed when at 
the sn-2 in the first 5 hours of feeding; however, no differences were in absorption were observed after 24 
hours. While we did see differences in absorption of DHA, these differences may be due to having mice 
on a moderately high fat diet, where diet composition could possibly interfere with complete digestion 
and absorption of dietary lipids.  
Yang et al. [208] showed TG hydrolysis with pancreatic lipase was slower when hydrolyzing TG 
with DHA and EPA. Also, they showed an even greater increase in hydrolysis time for TGs having more 
than 1 PUFA attached. With most of the DHA in FO at the sn-2 position, TG hydrolysis is faster than at 
the sn-1/3 position [208]. The DHA in AO is mostly at the sn-1/3 position, and since the DHA in this oil 
is concentrated to a greater extent than in FO, some of its TGs will have multiple DHA esters that will 
further slow its hydrolysis. This effect may explain why we see differences in absorption while others 
have not used different sources of lipids [3]. Studies comparing positional oils of sn-2 and sn-1/3 DHA 
enriched TGs report the same pattern where a greater accumulation of DHA occurred in lymph from 
sources primarily at the sn-2 position, compared to primarily at the sn-1/3 position, in the first hours after 
ingestion, however no differences were detected after 24 hours [204]. Valenzuela et al. [209] showed that 
supplementation with DHA, in the form of a 2-MG, resulted in greater tissue accumulation than the same 
amount of DHA administered from algae oil, which coincides with our FO model that has high 
enrichment of DHA at the sn-2 position. Greater absorption of DHA by the FO-fed mice compared to the 
AO-fed mice is primarily due to the differences in DHA enrichment at the sn-2 position.  
Experimentally Christensen et al. [4] showed feeding rats FO versus seal oil, which has 1/3 
enrichment for EPA/DHA, TGs in the chylomicrons mirrored dietary TG content. This similarity is 
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primarily due to TG re-esterifying through the 2-MG pathway once they are absorbed [48], so the fatty 
acids at the sn-2 position in dietary TGs stay at the sn-2 position once re-esterified.  However, this does 
not support our data in terms of the greater accretion of EPA from FO because we did not see an 
enrichment of EPA at the sn-2 position for FO. One possible explanation for the differences in EPA 
incorporation could be differing effects of LPL from the different sources. LPL is regulated by some of 
the same genes that EPA and DHA affect, mainly peroxisome proliferator-activated receptor γ (PPAR) 
and liver x receptor (LXR); these transcription factors can activate LPL transcription. Khan et al. [122] 
showed that omega-3 supplementation increased LPL mRNA in adipose tissue, which PPARγ has been 
shown to regulate. Harris et al. [210] showed, in patients given FO versus olive oil supplements, that FO 
supplementation increased LPL activity. Park and Harris [193] showed that omega-3 supplementation 
increased chylomicron clearance rate, as opposed to an olive oil control, and didn’t affect chylomicron 
secretion. However, with an increase in LPL activity, more EPA from FO would be incorporated into the 
tissues where EPA is preferentially incorporated into phospholipids [211] and possibly used less readily 
for oxidation. Harris et al. [210] showed that omega-3 supplementation in rats increased LPL hydrolysis 
of TGs without an increase in LPL protein levels.  
Another possibility could be that something else in YO is causing EPA to be used by the small 
intestine instead of being repackaged into chylomicrons. Consequently, it is not incorporated into the 
adipose and muscle tissue at a similar degree as FO. It is possible that the different sources of omega-3’s 
affect chylomicron composition in different ways, possibly changing the ratio of apoC-II, a LPL cofactor, 
and apoC-III, an inhibitor of LPL, in the chylomicrons or by changing the phospholipid to TG ratio in the 
chylomicrons which would affect tissue incorporation [210]. Albeit, different positional differences for 
omega-3s have no effect on the size of chylomicrons being secreted [212].  
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In conclusion, DHA from FO seems to be more available as compared to an algae oil source. This 
difference could be attributed to the enrichment of DHA at the sn-2 position of the TG in FO. FO-fed 
mice had greater DHA accretion in adipose when compared to AO-fed mice, and greater accretion of 
EPA in muscle and adipose compared to YO-fed mice.   
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Figures and Tables 
a.        b.  
  
c.           d. 
  
Figure 1. Reaction of pancreatic lipase [213]: Diagram of the hydrolysis of TG by lipase. The aspartic 
acid forms a hydrogen  bond with the serine causing it to act as a nucleophile and attack the carbonyl 
group of the TG (a). The tetrahedral intermediate is stabilized by the oxyanion hole between the leucine 
and phenylalanine. The carbonyl reforms with glycerol acting as a leaving group (b). A water molecule 
donates a proton to histidine to create a hydroxl anion which attacks the lipid (c) forming another 
tetrahedral intermediate again stabilized in the oxyanion hole. The carbonyl is reformed (d) and the fatty 
acid diffuses away. 
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Figure 2. Chylomicron formation [206]: Model of TG repackaging into chylomicron. apoB is 
translocated into the ER where it interacts with TG (1) and microsomal triacylglycerol transfer protein 
(MTTP) helps it in correctly folding into apoB48 (1a). When lipid is not present the apoB is degraded 
(1b). MTTP is also involved in shuttling TGs into the ER lumen (2). The TGs collect and fuse in the ER 
lumen, aided by MTTP (3). Once the droplet becomes a pre-chylomicron transfer vesicle (PCTV) it 
interacts with CD36 to help budding, fatty acid binding protein 1(FABP1) for transport, and coatomer II 
proteins (COPII) for aid in reaching the golgi (4). Once fused with the golgi the pre-chylomicron 
undergoes more processing with more apolipoproteins added as well as glycosylation of apoB48 (5). The 
chylomicron is then transported to the basolateral membrane and enters the lymph.  
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Table 1 Composition of experimental diets 
Ingredient(g/kg)
1 SO
2 
FO
2
 AO
2
 YO
2
 AO+YO
2
 
Isolated Soy Protein 200 200 200 200 200 
Cornstarch 345.42 345.42 345.42 345.42 345.42 
Dextronized Cornstarch 132 132 132 132 132 
Sucrose 100 100 100 100 100 
Cellulose 50 50 50 50 50 
Soy Oil 120 - 92.7 97.79 70.49 
Fish Oil  - 120 - - - 
Algae Oil  - - 27.3 - 27.3 
Yeast Oil  - - - 22.21 22.21 
AIN-93G Mineral Mix 35 35 35 35 35 
AIN-93G Vitamin Mix 10 10 10 10 10 
L-Cysteine 2.54 2.54 2.54 2.54 2.54 
L-Methionine 2.54 2.54 2.54 2.54 2.54 
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 
1
All numbers presented as g/kg of diet. Algae oil obtained from Martek Biosciences and yeast oil obtained from 
Futurebiotics. All other ingredients were obtained from Dyets Inc.  
2
SO=Soy Oil-fed mice, FO=Fish Oil, AO=Algae Oil, YO=Yeast Oil, AO+YO=Algae Oil + Yeast Oil. 
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Table 2 Fatty acid percent composition of dietary oils 
Fatty Acid
1 
Fish Yeast Algae Soy 
C10 ND
2 
ND
 
1.51 ND 
C12 0.25 ND
 
7.98 ND 
C13 0.12 ND
 
ND
 
ND 
C14 15.15 0.13 19.38 0.06 
C14:1 0.11 ND
 
0.49 ND 
C15 1.41 0.16 ND
 
0.01 
C15:1 0.03 ND
 
ND
 
ND 
C16 25.76 3.63 12.92 10.00 
C16:1 16.69 0.55 3.51 0.08 
C17 0.80 0.36 0.02 0.09 
C17:1 0.04 0.02 0.02 0.12 
C18 3.34 2.39 0.80 3.30 
C18:1n9t 0.16 0.21 ND
 
0.05 
C18:1n9c 8.39 5.19 25.12 19.75 
C18:2n6t 0.02 0.15 0.07 0.00 
C18:2n6c 1.66 19.98 1.59 57.06 
C20 0.16 0.02 0.06 0.22 
C18:3n6 0.42 0.33 ND
 
0.23 
C20:1 0.58 0.06 0.06 0.39 
C18:3n3 1.85 1.35 0.04 8.16 
C21 0.04 0.76 ND ND 
C20:2 3.94 1.90 0.09 0.15 
C22 0.05 0.04 0.09 0.22 
C20:3n6 0.18 2.92 ND 0.03 
C22:1n9 0.06 0.04 ND 0.01 
C20:3n3 0.18 0.22 ND ND 
C23 0.75 0.73 ND 0.01 
C22:2 1.23 1.05 ND ND 
C24 0.04 0.79 ND 0.04 
C20:5n3 10.54 56.81 0.47 0.01 
C24:1 0.18 0.14 ND 0.01 
C22:6n3 5.86 0.08 25.79 ND 
1
Percent of fatty acids in the oils used to make the dietary  
treatments, based on fatty acids identified compared to the 
standard used.  
2
Not detected 
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Table 3 Body composition data of mice 
 Week SO
1 
FO
1 
AO
1 
YO
1 
AO+YO
1 
P Value SEM 
Final Body 
Weight (g)
2 
2 37.20 37.62 37.73 35.79 37.98 0.109 0.61 
 4 39.86 40.08 39.68 40.15 40.92 0.928 1.02 
Average Daily 
Feed Intake 
(g/d)
2 
2 6.25 6.05 5.17 5.80 5.43 0.065 0.28 
 4 5.75 5.67 5.91 5.76 5.10 0.362 0.30 
Relative Brain 
Weight (% of 
body weight)
2 
2 
ab
1.29 a1.29 
a
1.26 
b
1.37 
a
1.24 0.016 0.03 
 4 1.14 1.13 1.18 1.12 1.11 0.863 0.05 
Relative Liver 
Weight (% of 
body weight)
2 
2 
c
4.50 
a
5.16 
bc
4.71 
ab
4.96 
abc
4.79 0.015 0.13 
 4 
b
4.54 
a
5.29 
b
4.69 
b
4.56 
b
4.62 0.003 0.14 
Relative Heart 
Weight (% of 
body weight)
2 
2 0.50 0.49 0.46 0.45 0.45 0.105 0.02 
 4 0.48 0.49 0.50 0.47 0.52 0.455 0.02 
Body Fat 
Index
2 
2 
ab
2.94 
a
2.54 
ab
2.94 
a
2.52 
b
3.18 0.098 0.20 
 4 4.68 3.39 3.93 3.63 4.07 0.316 0.44 
1
SO=Soy Oil-fed mice, FO=Fish Oil-fed mice, AO=Algae Oil-fed mice, YO=Yeast Oil-fed mice, AO+YO=Algae 
Oil + Yeast Oil-fed mice. 
2
Final body weight in grams. Average daily feed intake throughout experiment in grams. Relative brain, liver, and 
heart measured by weight of (organ weight/final body weight)x100, represented in g/g body weight. Body fat index 
calculated as reteroperitoneal + epididymal fat pad weights/final body weight x 100. 
abc
 indicate significant 
differences between diets within week. 
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a.
 
b. 
 
Figure 3. Effect of dietary treatment on muscle fatty acids: Muscle EPA (a) and muscle DHA (b) fatty 
acid percent of mice (n=100) from week 2 and week 4. Percent calculated as fatty acid peak area/total 
identified fatty acid peak area x 100. Data expressed as means ± SEM. Different letters indicate 
significant differences between diets within week (P<0.05).   
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a. 
b. 
 
Figure 4. Effect of dietary treatment on adipose tissue fatty acids: Adipose EPA (a) and DHA (b) 
fatty acid percent of mice (n=100) from week 2 and week 4. Percent calculated as fatty acid peak 
area/total identified fatty acid peak area x 100. Data expressed as means ± SEM. Different letters indicate 
significant differences between diets within week (P<0.05).   
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a. 
 
b. 
 
Figure 5. Effect of dietary treatment on fecal fatty acid composition: Fecal EPA (a) and DHA (b) 
percent of total fecal fatty acids, calculated as fatty acid peak area/total fatty acids identified peak area. 
Data expressed as means ± SEM. 
abcd 
 indicate significant differences between diets within week (P<.05), 
yz
 represent differences between week within diet (P<0.05). 
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Figure 6. Thin Layer Chromatography of Oils: Picture of thin layer chromatography plate of the oils. 
Oils were spotted and assayed in hexane:diethyl ether:acetic acid solution and charred for visibility. From 
left to right the oils are soy oil, fish oil, algae oil, and yeast oil. The TLC standard run contains, in order 
from top to bottom, free fatty acid, triglyceride, cholesteryl ester, free cholesterol, and phospholipid 
which is not visible. Next is triglyceride standard and then free fatty acid standard. The dietary oils appear 
to only have bands where the triglyceride should be with no other visible bands.  
 
 
 
 
 
 
 
 
 
 
 
 
SO       FO       AO     YO           TLC         TG         FFA 
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Table 4. Positional analysis of fatty acids on the triglycerides of the oils 
 
Total% 
sn1/3% of 
total 
sn2% of 
total 
SO EPA 0 0 0 
FO EPA 15.14 53.96 46.04 
AO EPA 0.03 100 0 
YO EPA 60.99 68.32 31.64 
SO DHA 0 0 0 
FO DHA 14.04 38.03 61.97 
AO DHA 43.16 59.78 40.22 
YO DHA 0 0 0 
Dietary oils used were digested using a lipase and separated on thin layer chromatography. The monoglyceride 
portion was extracted and analyzed for fatty acids to measure sn-2 position. Data are expressed as percent of fatty 
acid in total fatty acids of oil, percent of the fatty in sn-1/3 position, and percent of the fatty acid in sn-2 position. 
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